First scorpion sting drug receives FDA approval

by Deborah Braconnier report
A regular scorpion...

The FDA has announced the approval of Anascorp, the first drug designed to specifically treat and counteract the venomous stings of scorpions.

The centruroides scorpion is the most common type of scorpion found in the United States and is responsible for an average 11000 stings a year in Arizona alone. In 2009, 17000 stings were reported to the Arizona Poison and Drug Information Center.

Scorpion stings can cause reactions of a serious nature such as , breathing problems, blurred vision, fluid in the lungs, excess saliva, trouble swallowing, slurred speech, muscle twitching, loss of muscle coordination and difficulty walking. Children and infants are at the greatest risk of severe reactions.

The new drug was the first drug to be fully developed in a Latin American country, in this case Mexico, and then approved by the . Anascorp is derived from the horse plasma taken from horses that have received a immunization and may cause in individuals who have a sensitivity to horse proteins.

Anascorp is considered an “orphan” drug and received priority review. An orphan drug is one that is specifically designed to treat rare conditions and diseases.

The new drug was rated based on a clinical trial including 15 children with neurological symptoms present after stings. Eight of the children received Anascorp and seven received a placebo. The eight children receiving the drug showed improvement and loss of symptoms within four hours of treatment while only one of the placebo children improved. Efficacy and safety data were also collected from some 1500 patients.

Side effects caused by Anascorp include nausea, vomiting, fever, runny nose, rash, itching, headache and muscle pain.

Rare Disease Therapeutics Inc. holds the license for Anascorp and it is distributed by Accredo Health Group Inc. out of Tennessee. It is currently being manufactures by a company in Tlalpan, Mexico.

add to favorites email to friend print save as pdf

Related Stories

Genetic analysis reveals secrets of scorpion venom

Jul 01, 2009

Transcriptomic tests have uncovered the protein composition of venom from the Scorpiops jendeki scorpion. Researchers writing in the open access journal BMC Genomics have carried out the first ever venom analysis in this arach ...

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.